Rose Lab Lady Davis Institute · McGill
  1. Home
  2. Publications

Publications

Publications by Dr. April Rose and members of the Rose Lab, from clinical trials to molecular mechanisms of resistance.

Paper of the Month · January 2026

Binimetinib and encorafenib for the treatment of advanced solid tumors with non‑V600E BRAF mutations: results from the Phase II BEAVER trial

A. A. N. Rose*‡, J. Maxwell*, E. Rousselle*, C. L. Mukonoweshuro, I. E. Elkholi, M. Riaud, M. Biondini, E. Cianfarano, I. Soria‑Bretones, C. Tobin, M. McGuire, R. W. Y. Law, A. J. Elia, B. X. Wang, I. King, T. Zhang, T. Pugh, Z. Saeed Kamil, M. O. Butler, F. A. Shepherd, N. Leighl, A. Abdul Razak, A. Hansen, S. Saibil, P. L. Bedard, P. M. Siegel, L. L. Siu, D. W. Cescon, A. Spreafico*. Equal Contribution ‡Co‑Corresponding Authors. Nature Communications. 2026. 17:1323.

Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types, yet there are no established targeted therapies with proven efficacy for these cancers.

The investigator-initiated Phase II BEAVER trial (NCT03839342) evaluated BRAF and MEK inhibitors in patients with non-V600E BRAF mutations. By analyzing patient tumors, circulating tumor DNA, patient-derived xenografts and cell lines, the team uncovered MAPK-dependent and independent mechanisms of resistance, and found that combining CDK4/6 or SHP2 inhibitors with BRAF/MEK inhibitors was more effective in preclinical models.

Read the paper
Binimetinib and encorafenib for the treatment of advanced solid tumors with non‑V600E BRAF mutations: results from the Phase II BEAVER trial

50 publications · Dr. Rose in bold · Lab members highlighted

2026

  1. mTOR inhibition enhances the antitumor efficacy of RAF dimer–MEK blockade by inhibiting the ATF4–MTHFD2 pathway

    F. Cai, F. Huang, C. Goncalves, H. Srikannan, N. Gagnon, E. M. Guettler, L. Mukeba‑Harchies, J. Maxwell, J. Su, K. Bijian, F. Journe, A. A. N. Rose, A. Orthwein, S. V. del Rincón, W. H. Miller Jr. Cell Death & Disease. 2026. Accepted, In press.

    DOI 10.1038/s41419-026-08836-5

  2. Repertoire and clinical hierarchy of AR locus alterations in castration‑resistant prostate cancer

    T. Virtanen, E. Kwan, K. Parekh, J. Bacon, C. F. Huang, I. P. L. Yu, L. Ryyppö, C. Bernales, G. Donnellan, C. Tam, J. Sipola, J. Nikkola, G. Vandekerkhove, S. H. Tolmeijer, K. Kukkonen, Adelia, B. Eigl, D. Finch, R. Gagnon, Y. Hamid, E. Hardy, D. Khalaf, C. Kollmannsberger, J. Lavoie, C. Maurice‑Dror, S. Miller, L. Nappi, K. Noonan, S. Parimi, A. Riminchan, E. Sartori‑Mueller, M. Soleimani, J. Vergidis, M. Zulfiqar, A. Hansen, S. Hotte, M. Jafri, M. Kolinsky, S. Mukherjee, M. Ong, A. A. N. Rose, W. Tu, E. Winquist, A. Bergman, K. van der Zande, W. Zwart, N. Mehra, N. van Erp, J. Zhao, D. Rathkopf, C. Barbieri, D. Quigley, M. Nykter, N. Lack, K. N. Chi, M. Annala, A. Wyatt. Annals of Oncology. 2026. Vol. 37, Issue 3, Pages 388–402.

    Article DOI 10.1016/j.annonc.2025.10.1236

  3. Binimetinib and encorafenib for the treatment of advanced solid tumors with non‑V600E BRAF mutations: results from the Phase II BEAVER trial

    A. A. N. Rose*‡, J. Maxwell*, E. Rousselle*, C. L. Mukonoweshuro, I. E. Elkholi, M. Riaud, M. Biondini, E. Cianfarano, I. Soria‑Bretones, C. Tobin, M. McGuire, R. W. Y. Law, A. J. Elia, B. X. Wang, I. King, T. Zhang, T. Pugh, Z. Saeed Kamil, M. O. Butler, F. A. Shepherd, N. Leighl, A. Abdul Razak, A. Hansen, S. Saibil, P. L. Bedard, P. M. Siegel, L. L. Siu, D. W. Cescon, A. Spreafico*. Equal Contribution ‡Co‑Corresponding Authors. Nature Communications. 2026. 17:1323.

    DOI 10.1038/s41467-025-68076-7

2025

  1. Defining the prognostic significance of BRAF V600E in early‑stage colon cancer: a systematic review and meta‑analysis

    M. Dankner, L. Dubé, M. Sorin, A. J. B. Stein, A. Nowakowski, L. Park, J. Magrill, A. Lazaratos, J. M. Romero, G. Batist, P. Kavan, A. A. N. Rose, K. Ma Current Oncology. 32(11), 624 (2025).

    DOI 10.3390/curroncol32110624

  2. Evaluating the role of liquid biopsy to detect pathogenic Homologous Recombination Repair (HRR) gene alterations in metastatic prostate cancer

    Labidi, B. Jiao, S. Tam, P. Fallah, A. Salehi, R. Rajan, M. Alameldine, F. Brimo, W. Foulkes, A. Papadakis, N. Kaul, A. Spatz, C. Ferrario, R. R. Saleh, A. A. N. Rose‡ Cancers. 2025;17(21):3427.

    DOI 10.3390/cancers17213427

  3. The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: a pan‑Canadian approach to accelerate cancer precision medicine

    The Terry Fox Research Institute Marathon of Hope Cancer Centers Network* Cancer Cell. 2025. Accepted; Online ahead of print.

    DOI 10.1016/j.ccell.2025.03.014

  4. High Ki67 is associated with increased risk of distant recurrence in low‑risk breast cancer

    Labidi, N. Mulla, I. E. Elkholi, M. Pilon, A. A. N. Rose, L. Panasci, C. Ferrario, M. Basik, P. Fallah. Clinical Breast Cancer. 2025.

    DOI 10.1016/j.clbc.2025.04.001

  5. Clinical activity of Mitogen‑Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)‑mutated metastatic cancers

    Dankner, E. Rousselle, S. Petrecca, F. Fabi, A. Nowakowski, A. Lazaratos, C. V. Rajadurai, A. Stein, D. Bian, P. Tai, A. Belaiche, M. Li, A. Quaiattini, N. Normanno, M. Arcila, A. Elkrief, D. B. Johnson, M. Ladanyi, A. A. N. Rose‡ JCO Precision Oncology. 9, e2400199 (2025).

    DOI 10.1200/PO.24.00199

  6. Clinical outcomes of HER2+ and HER2‑low metastatic breast cancer patients with and without central nervous system metastases treated with trastuzumab deruxtecan

    Lazaratos, M. Dankner, A. Hamouda, S. Labidi, V. Cohen, L. Panasci, J. E. Friedmann, F. Patenaude, C. Ferrario, M. Basik, A. A. N. Rose, P. Fallah Current Oncology. 32(1), 1 (2025).

    DOI 10.3390/curroncol32010001

2024

  1. How can we integrate the biology of breast cancer cell dormancy into clinical practice?

    I. Elkholi, A. A. N. Rose, J. Aguirre-Ghiso, J. F. Cote. (2024) Cancer Cell.

    DOI 10.1016/j.ccell.2024.05.023

  2. Osimertinib is associated with improved outcomes compared to first- and second-generation EGFR inhibitors in pre-treated but not untreated NSCLC leptomeningeal metastases

    D. Bian, A. Lazaratos, S. M. Maritan, A. Quaiattini, Z. Zeng, Z. Zhu, S. T. Ugur, R. Malani, Y. J. Kim, E. Ichihara, V. Cohen, A. A. N. Rose, N. Bouganim, M. Dankner. (2024) Heliyon. Pages e29668 E-pub ahead of print.

    DOI 10.1016/j.heliyon.2024.e29668

  3. A Phase 2, Single-Arm Trial Evaluating 131I-PSMA-1095 Targeted Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer

    F. Liu, C. Ferrario, P. Fallah, A. A. N. Rose, S. Labidi, A. Mamo, S. M. Probst. (2024) Nuclear Medicine Communications. Accepted – Online ahead of print.

    DOI 10.1097/MNM.0000000000001858

  4. The evolving treatment landscape for BRAF-mutated non-small cell lung cancer

    M. Dankner, J. Maxwell, A. A. N. Rose. (2024) (2024). Translational Lung Cancer Research. 2024;13(4):930-935.

    DOI 10.21037/tlcr-24-117

  5. Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicenter retrospective cohort study

    S. Labidi, N. Meti, R. Barua, J. Riromar, A. Hansen, D. M. Jiang, N. Fallah-Rad, S. S. Sridhar, C. Ferrario, R. Pezo, S. Cheng, A. G. Sacher, A. A. N. Rose. (2024) BMJ Open. 2024;14:e081480.

    DOI 10.1136/bmjopen-2023-081480

  6. Characterizing the clinical, genomic, and transcriptomic landscape of BRAF mutant cancers

    S. Kazandjian*, E. Rousselle*, M. Dankner, D. W. Cescon, A. Spreafico, K. Ma, P. Kavan, G. Batist, A. A. N. Rose. (2024) Cancers 16(2),445. *Equal Contribution.

    DOI 10.3390/cancers16020445

  7. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

    M. Riaud, J. Maxwell, I. Soria-Bretones, M. Dankner, M. Li, A. A. N. Rose. (2024) Nature Reviews Cancer. 24:105-122

    DOI 10.1038/s41568-023-00650-x

2023

  1. Analysis of the circulating metabolome of patients with cutaneous, mucosal and uveal melanoma reveals distinct metabolic profiles with implications for response to immunotherapy

    M. Vilbert, E. C. Koch, A. A. N. Rose, R. C. Laister, D. Gray, V. Sotov, S. Penny, A. Spreafico, D. Hogg, D. M. Pinto, M. O. Butler, S. D. Saibil. (2023) Cancers 15(14), 3708

    DOI 10.3390/cancers15143708

  2. Intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

    A. Lazaratos, S. M. Maritan, A. Quaiattini, A. Darlix, R. Ivica, E. Ferraro, G. Griguolo, A. Pellerino, S. Hofer, W. Jacot, H. Stemmler, M. P.H. van den Broek, N. Dobnikar, F. Panet, Z. Lahijanian, A. Morikawa, A. D. Seidman, R. Soffietti, L. Panasci, K. Petrecca, A. A. N. Rose, N. Bouganim, M. Dankner. (2023) The Breast.

    DOI 10.1016/j.breast.2023.04.008

  3. Non-small cell lung cancer: how to manage BRAF-mutated disease

    G. Guaitoli, L. Zollo, M. Tiseo, M. Dankner, A. A. N. Rose, F. Facchinetti. (2023) Drugs in Context. 2023; 12:2022-11-3.

    DOI 10.7573/dic.2022-11-3

  4. Gender Disparities among Graduates of a Canadian MD-PhD Program

    J. M. Romero, M. Sorin, M. Danker, H. Whittaker, A. A. N. Rose, J. Trasler, M. Eisenberg. (2023) Clinical and Investigative Medicine. 46(1)2023.

    DOI 10.25011/cim.v46i1.39965

  5. Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

    Sathyen A Prabhu, Omar Moussa, Christophe Gonçalves, Judith H LaPierre, Hsiang Chou, Fan Huang, Vincent R Richard, Pault YM Ferruzo, Elizabeth M Guettler, Isabel Soria-Bretones, Laura Kirby, Natascha Gagnon, Jie Su, Jennifer Silvester, Sai Sakktee Krisna, April A. N. Rose, Karen E Sheppard, David W Cescon, Frédérick A Mallette, Rene P Zahedi, Christoph H Borchers, Sonia V Del Rincon, Wilson H Miller Jr. Mol Cancer Ther (2023) 22 (2): 192–204.

    Article

2022

  1. Clinical activity of mitogen-activated protein kinase–targeted therapies in patients with non–V600 BRAF-mutant tumors

    Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A Nebhan, Ibiayi Dagogo-Jack, Nathaniel J Myall, Georg Richtig, Jillian WP Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A Sosman, Scott Kopetz, Vivek Subbiah, Michael A Davies, Anna L Groover, Ryan J Sullivan, Keith T Flaherty, Douglas B Johnson, Andrea Benedetti, David W Cescon, Anna Spreafico, George Zogopoulos, April A. N. Rose. JCO Precision Oncology no. 6 (2022) e2200107. Published online August 17, 2022.

    DOI 10.1200/PO.22.00107

  2. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER+ breast cancer with mitotic aberrations

    Isabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, Jennifer Cruickshank, Samah El Ghamrasni, Wail Ba-Alawi, Graham C Fletcher, Reza Kiarash, Mitchell J Elliott, Jordan J Chalmers, Andrea C Elia, Albert Cheng, April AN Rose, Mark R Bray, Benjamin Haibe-Kains, Tak W Mak, David W Cescon. SCIENCE ADVANCES. 8(36).

    DOI 10.1126/sciadv.abq4293

  3. Melanomas with concurrent BRAF non-p. V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

    Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Cell Rep. 2022 Apr 5;39(1):110634.

    Article DOI 10.1016/j.celrep.2022.110634

  4. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

    Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM. Oncogene. 2022 Mar;41(12):1701-1717. Epub 2022 Feb 2.

    Article DOI 10.1038/s41388-022-02206-z

  5. Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report

    Sonia Rodriguez-Ramirez, Kevin Yau, Abhijat Kitchlu, Rohan John, April A. N. Rose, David Hogg, S Joseph Kim. Kidney Medicine. Volume 4, Issue 5, May 2022, 10046

    Article

2021

  1. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

    Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. J Immunother Cancer. 2021 Jan;9(1):e001931.

    Article DOI 10.1136/jitc-2020-001931

  2. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

    Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A. J Immunother Cancer. 2021 Jan;9(1):e001642.

    Article DOI 10.1136/jitc-2020-001642

  3. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors

    Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A. Cancers (Basel). 2021 Jul 20;13(14):3640.

    Article DOI 10.3390/cancers13143640

  4. Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement Initiative

    Nadler MB, Rose AAN, Prince R, Eng L, Lott A, Grant RC, Jones JM, Enright K. JCO Oncol Pract. 2021 Apr;17(4):e593-e602. Epub 2020 Dec 8

    Article DOI 10.1200/OP.20.00432

2019

  1. BRAF Mutation Class and Clinical Outcomes-Letter

    Dankner M, Rose AAN. Clin Cancer Res. 2019 May 15;25(10):3188.

    Article DOI 10.1158/1078-0432.CCR-19-0080

  2. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma

    Rose AAN. Drugs Today (Barc). 2019 Apr;55(4):247-264.

    Article DOI 10.1358/dot.2019.55.4.2958476

2018

  1. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas

    Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN. Clin Cancer Res. 2018 Dec 15;24(24):6483-6494. Epub 2018 Jun 14.

    Article DOI 10.1158/1078-0432.CCR-17-3384

  2. Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

    Dankner M, Rose AAN. Br J Cancer. 2018 May;118(9):1276-1277. Epub 2018 Mar 22.

    Article DOI 10.1038/s41416-018-0012-2

  3. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

    Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Oncogene. 2018 Jun;37(24):3183-3199. Epub 2018 Mar 15.

    Article DOI 10.1038/s41388-018-0171-x

2017

  1. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer

    Rose AAN, Biondini M, Curiel R, Siegel PM. Pharmacol Ther. 2017 Nov;179:127-141. Epub 2017 May 22.

    Article DOI 10.1016/j.pharmthera.2017.05.010

2016

  1. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

    Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. Clin Cancer Res. 2016 Dec 15;22(24):6088-6098. Epub 2016 Aug 11.

    Article DOI 10.1158/1078-0432.CCR-16-1192

2015

  1. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases

    Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, Carmona E, Tam CE, Mes-Masson AM, Siegel PM. Breast Cancer Res. 2015 Mar 27;17(1):45.

    Article DOI 10.1186/s13058-015-0558-3

  2. GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis

    Maric G, Annis MG, Dong Z, Rose AA, Ng S, Perkins D, MacDonald PA, Ouellet V, Russo C, Siegel PM. Oncogene. 2015 Oct;34(43):5494-504. Epub 2015 Mar 16.

    Article DOI 10.1038/onc.2015.8

2014

  1. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer

    Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L.J Clin Oncol. 2014 Nov 10;32(32):3619-25. Epub 2014 Sep 29.

    Article DOI 10.1200/JCO.2013.52.5683

2013

  1. Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis

    Rose AA, Elser C, Ennis M, Goodwin PJ. Breast Cancer Res Treat. 2013 Oct;141(3):331-9. Epub 2013 Oct 9.

    Article DOI 10.1007/s10549-013-2713-9

2010

  1. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties

    Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM.PLoS One. 2010 Aug 10;5(8):e12093.

    Article DOI 10.1371/journal.pone.0012093

  2. Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities

    Bemmo A, Dias C, Rose AA, Russo C, Siegel P, Majewski J.PLoS One. 2010 Aug 6;5(8):e11981.

    Article DOI 10.1371/journal.pone.0011981

  3. Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells

    Demers M, Rose AA, Grosset AA, Biron-Pain K, Gaboury L, Siegel PM, St-Pierre Y. Am J Pathol. 2010 Jun;176(6):3023-31. Epub 2010 Apr 9.

    Article DOI 10.2353/ajpath.2010.090876

  4. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

    Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM. Clin Cancer Res. 2010 Apr 1;16(7):2147-56.

    Article DOI 10.1158/1078-0432.CCR-09-1611

  5. Emerging therapeutic targets in breast cancer bone metastasis

    Rose AA, Siegel PM. Future Oncol. 2010 Jan;6(1):55-74.

    Article DOI 10.2217/fon.09.138

2009

  1. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis

    Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguère V, Siegel PM, Bouchard M. Oncogene. 2009 Jul 23;28(29):2634-42. Epub 2009 Jun 1.

    Article DOI 10.1038/onc.2009.126

2007

  1. Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?

    Rose AA, Siegel PM. Breast Cancer Res. 2007;9(6):403.

    Article DOI 10.1186/bcr1791

  2. Osteoactivin promotes breast cancer metastasis to bone

    Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM. Mol Cancer Res. 2007 Oct;5(10):1001-14.

    Article DOI 10.1158/1541-7786.MCR-07-0119

2006

  1. Breast cancer-derived factors facilitate osteolytic bone metastasis

    Rose AA, Siegel PM. Bull Cancer. 2006 Sep;93(9):931-43.

    Article

View all publications on PubMed